Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 301–400 of 1,008
Genetics of Parkinson's disease
Cherian, A., & Divya, K. P. (2020) · Acta Neurologica Belgica · doi:10.1007/s13760-020-01473-5 · Cited by 131
Reza, S., Ugorski, M., & Suchański, J. (2021) · Glycobiology · doi:10.1093/glycob/cwab046 · Cited by 114
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Arena, G., Sharma, K., Agyeah, G., Krüger, R., Grünewald, A., & Fitzgerald, J. C. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01207-5 · Cited by 128
Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling
Rana, H. Q., Balwani, M., Bier, L., & Alcalay, R. N. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.107 · Cited by 118
Variants in saposin D domain of prosaposin gene linked to Parkinson’s disease
Oji, Y., Hatano, T., Ueno, S.-I., Funayama, M., Ishikawa, K.-I., Okuzumi, A., Noda, S., Sato, S., Satake, W., Toda, T., et al. (2020) · Brain · doi:10.1093/brain/awaa064 · Cited by 116
Self-citationPharmacological chaperone therapy for Gaucher disease: a patent review
Benito, J. M., García Fernández, J. M., & Mellet, C. O. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.569162 · Cited by 114
Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease
Stojkovska, I., Krainc, D., & Mazzulli, J. R. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2704-y · Cited by 110
“The clinical progression of PD patients with GBA1 mutations is often more rapid compared to patients without mutations and there is a greater risk for cognitive impairment (Brockmann et al. 2011; McNeill et al. 2012; Neumann et al. 2009; Sidransky et al. 2009; Tan et al. 2007).”
Parkinson’s disease: experimental models and reality
Jiang, P., & Dickson, D. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1788-5 · Cited by 111
The Vicious Cycle Between α ‐Synuclein Aggregation and Autophagic‐Lysosomal Dysfunction
Bellomo, G., Paciotti, S., Gatticchi, L., & Parnetti, L. (2019) · Movement Disorders · doi:10.1002/mds.27895 · Cited by 127
“Whereas GBA1 homozygous mutations cause Gaucher’s disease (GD), a lysosomal storage disorder, heterozygous GBA1 mutation carriers have a 5- to 6-fold increased risk to develop PD.34 Some researchers suggest that GBA1 mutations should be considered causative factors for PD.35 However, the penetrance of PD in GBA1 mutat…”
BackgroundInfluentialStojkovska, I., Wani, W. Y., Zunke, F., Belur, N. R., Pavlenko, E. A., Mwenda, N., Sharma, K., Francelle, L., & Mazzulli, J. R. (2021) · Neuron · doi:10.1016/j.neuron.2021.10.032 · Cited by 129
α-Synuclein pathology as a target in neurodegenerative diseases
Park, H.-J., Kam, T., Dawson, V. L., & Dawson, T. M. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01043-w · Cited by 125
International Parkinson’s Disease Genetics Consortium (IPGDC), Jansen, I. E., Ye, H., Heetveld, S., Lechler, M. C., Michels, H., Seinstra, R. I., Lubbe, S. J., Drouet, V., Lesage, S., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1147-9 · Cited by 117
Self-citationBrekk, O. R., Honey, J. R., Lee, S., Hallett, P. J., & Isacson, O. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003021117 · Cited by 114
Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation
Martínez‐Vicente, M. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.03.005 · Cited by 123
LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function
Wallings, R., Connor-Robson, N., & Wade-Martins, R. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz088 · Cited by 115
Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease
Pihlstrøm, L., Axelsson, G., Bjørnarå, K. A., Dizdar, N., Fardell, C., Forsgren, L., Holmberg, B., Larsen, J. P., Linder, J., Nissbrandt, H., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.019 · Cited by 120
Heritability of Parkinson disease in Swedish twins: a longitudinal study
Wirdefeldt, K., Gatz, M., Reynolds, C. A., Prescott, C. A., & Pedersen, N. L. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.017 · Cited by 111
Ginns, E. I., Mak, S. K., Ko, N., Karlgren, J., Akbarian, S., Chou, V., Guo, Y., Lim, A., Samuelsson, S. J., LaMarca, M. L., et al. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.12.003 · Cited by 125
Hyposmia and cognitive impairment in Gaucher disease patients and carriers
McNeill, A., Duran, R., Proukakis, C., Bras, J., Hughes, D., Mehta, A., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Movement Disorders · doi:10.1002/mds.24945 · Cited by 111
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease
Beavan, M. S., & Schapira, A. H. V. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.849003 · Cited by 107
Unfolded protein response in Gaucher disease: from human to Drosophila
Maor, G., Rencus‐Lazar, S., Filocamo, M., Steller, H., Segal, D., & Horowitz, M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-140 · Cited by 119
Lysosome and Inflammatory Defects in GBA1‐Mutant Astrocytes Are Normalized by LRRK2 Inhibition
Sanyal, A., DeAndrade, M. P., Novis, H. S., Lin, S., Chang, J., Lengacher, N., Tomlinson, J. J., Tansey, M. G., & LaVoie, M. J. (2020) · Movement Disorders · doi:10.1002/mds.27994 · Cited by 113
“Near-complete loss of GCase activity causes the lysosomal storage disorder, Gaucher’s disease, where ~300 different mutations in GBA1 drive disease through autosomal recessive inheritance.28 Increasing evidence, however, associates partial GCase loss of function with parkinsonism as heterozygous carriers of GBA1 mutat…”
BackgroundInfluentialMembrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity
Yap, T. L., Velayati, A., Sidransky, E., & Lee, J. C. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.11.010 · Cited by 111
Self-citationA GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy
Richter, F., Fleming, S. M., Watson, M. B., Lemesre, V., Pellegrino, L. J., Ranes, B. E., Zhu, C., Mortazavi, F., Mulligan, C. K., Sioshansi, P. C., et al. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0294-x · Cited by 114
Kawamata, J., & Shimohama, S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110173 · Cited by 111
LRRK2 and the Endolysosomal System in Parkinson’s Disease
Erb, M. L., & Moore, D. J. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202138 · Cited by 121
Lysosomal exocytosis releases pathogenic α-synuclein species from neurons in synucleinopathy models
Xie, Y. X., Naseri, N. N., Fels, J. A., Kharel, P., Na, Y., Lane, D., Burré, J., & Sharma, M. (2022) · Nature Communications · doi:10.1038/s41467-022-32625-1 · Cited by 117
Self-citationSMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease
Alcalay, R. N., Mallett, V., Vanderperre, B., Tavassoly, O., Dauvilliers, Y., Wu, R. Y. J., Ruskey, J. A., Leblond, C. S., Ambalavanan, A., Laurent, S. B., et al. (2019) · Movement Disorders · doi:10.1002/mds.27642 · Cited by 110
“These results suggest that although only a small proportion of PD patients have SMPD1 variants that increase the risk for PD, ASMase activity may have a role in PD.”
BackgroundSelf-citationGlucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine
Blandini, F., Cilia, R., Cerri, S., Pezzoli, G., Schapira, A. H. V., Mullin, S., & Lanciego, J. L. (2018) · Movement Disorders · doi:10.1002/mds.27583 · Cited by 115
Burbulla, L. F., Jeon, S., Zheng, J., Song, P., Silverman, R. B., & Krainc, D. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6870 · Cited by 112
“Mutations in GCase are linked to the lysosomal storage disorder Gaucher’s disease and represent the most common genetic risk factor for PD (4).”
Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease
Mullin, S., & Schapira, A. H. V. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.010 · Cited by 108
GBA Variants Influence Motor and Non-Motor Features of Parkinson’s Disease
Jesús, S., Huertas, I., Bernal‐Bernal, I., Bonilla‐Toribio, M., Cáceres‐Redondo, M. T., Vargas‐González, L., Gómez-Llamas, M., Carrillo, F., Calderón, E. J., Carballo, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167749 · Cited by 117
Pal, G., Mangone, G., Hill, E. J., Ouyang, B., Liu, Y., Lythe, V., Ehrlich, D., Saunders‐Pullman, R., Shanker, V., Bressman, S., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26302 · Cited by 104
Self-citationKey genes and convergent pathogenic mechanisms in Parkinson disease
Coukos, R., & Krainc, D. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00812-2 · Cited by 127
Animal models for Gaucher disease research
Farfel-Becker, T., Vitner, E. B., & Futerman, A. H. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.008185 · Cited by 105
Crosstalk between Lysosomes and Mitochondria in Parkinson's Disease
Plotegher, N., & Duchen, M. R. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00110 · Cited by 106
Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease
Oeda, T., Umemura, A., Mori, Y., Tomita, S., Kohsaka, M., Park, K., Inoue, K., Fujimura, H., Hasegawa, H., Sugiyama, H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.027 · Cited by 105
“…et al., 2013; Clark et al., 2007; Gan-Or et al., 2008; Kresojevic et al., 2015; Lwin et al., 2004; Malec-Litwinowicz et al., 2014; Mitsui et al., 2009; Neumann et al., 2009; Nichols et al., 2009; Seto-Salvia et al., 2012; Sidransky et al., 2009; Swan and SaundersPullman, 2013; Wang et al., 2012).”
BackgroundResultInfluentialThe Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions
Orme, T., Guerreiro, R., & Bras, J. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0874-y · Cited by 99
Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases
Novellino, F., Saccà, V., Donato, A., Zaffino, P., Spadea, M. F., Vismara, M., Arcidiacono, B., Malara, N., Presta, I., & Donato, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031115 · Cited by 101
Mitra, S., Anjum, J., Muni, M., Das, R. C., Rauf, A., Islam, F., Emran, T. B., Semwal, P., Hemeg, H. A., Alhumaydhi, F. A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112877 · Cited by 107
Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications
Balestrino, R., & Schapira, A. H. V. (2018) · The Neuroscientist · doi:10.1177/1073858417748875 · Cited by 95
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
Hallett, P. J., Engelender, S., & Isacson, O. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1532-2 · Cited by 104
Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies
Krohn, L., Öztürk, T. N., Vanderperre, B., Ouled Amar Bencheikh, B., Ruskey, J. A., Laurent, S. B., Spiegelman, D., Postuma, R. B., Arnulf, I., Hu, M. T. M., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25629 · Cited by 100
“Therefore, although the current evidence supports TMEM175 as the risk-associated gene in this locus, further studies are required to examine the potential role of DGKQ and GAK in PD. Previous genetic studies in idiopathic RBD suggested that whereas some of the genes that are associated with PD and DLB, such as GBA40 a…”
BackgroundInfluentialSelf-citationGlucocerebrosidase: Functions in and Beyond the Lysosome
Boer, D. E. C., van Smeden, J., Bouwstra, J. A., & Aerts, J. M. F. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030736 · Cited by 114
“Carriers of GD have a yet unexplained significantly increased (20-fold) risk for developing Parkinson disease (PD) and Lewy body dementia (LBD) [110–112].”
BackgroundNovel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability
Santoro, L., Breedveld, G. J., Manganelli, F., Iodice, R., Pisciotta, C., Nolano, M., Punzo, F., Quarantelli, M., Pappatà, S., Di Fonzo, A., et al. (2011) · neurogenetics · doi:10.1007/s10048-010-0259-0 · Cited by 103
Synucleinopathies: Where we are and where we need to go
Brás, I. C., Dominguez‐Meijide, A., Gerhardt, E., Koss, D., Lázaro, D. F., Santos, P. I., Vasili, E., Xylaki, M., & Outeiro, T. F. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14965 · Cited by 101
Jenner, P., Morris, H. R., Robbins, T. W., Goedert, M., Hardy, J., Ben-Shlomo, Y., Bolam, P., Burn, D., Hindle, J. V., Brooks, D., et al. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130175 · Cited by 100
Kett, L. R., Stiller, B., Bernath, M. M., Tasset, I., Blesa, J., Jackson-Lewis, V., Chan, R. B., Zhou, B., Di Paolo, G., Przedborski, S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0632-14.2015 · Cited by 100
How we manage Gaucher Disease in the era of choices
Revel‐Vilk, S., Szer, J., Mehta, A. B., & Zimran, A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15402 · Cited by 106
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Jasutkar, H. G., Oh, S. E., & Mouradian, M. M. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000133 · Cited by 111
Navarro-Romero, A., Fernández-González, I., Riera, J., Montpeyó, M., Albert-Bayo, M., López‐Royo, T., Castillo-Sanchez, P., Carnicer-Cáceres, C., Arranz, J. A., Castillo‐Ribelles, L., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00397-6 · Cited by 112
Papadopoulos, V. E., Nikolopoulou, G., Antoniadou, I., Karachaliou, A., Arianoglou, G., Emmanouilidou, E., Sardi, S. P., Stefanis, L., & Vekrellis, K. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy075 · Cited by 95
Ambrosi, G., Ghezzi, C., Zangaglia, R., Levandis, G., Pacchetti, C., & Blandini, F. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.008 · Cited by 102
Goldsmith, J. C., Bonham, V. L., Joiner, C. H., Kato, G. J., Noonan, A. S., & Steinberg, M. H. (2012) · American Journal of Hematology · doi:10.1002/ajh.22271 · Cited by 108
Variants associated with Gaucher disease in multiple system atrophy
Mitsui, J., Matsukawa, T., Sasaki, H., Yabe, I., Matsushima, M., Dürr, A., Brice, A., Takashima, H., Kikuchi, A., Aoki, M., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.185 · Cited by 100
Self-citationAutophagic pathways in Parkinson disease and related disorders
Xilouri, M., & Stefanis, L. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001803 · Cited by 113
Jo, J., Yang, L., Tran, H., Yu, W., Sun, A. X., Chang, Y. Y., Jung, B. C., Lee, S., Saw, T. Y., Xiao, B., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26166 · Cited by 105
Self-citationBiomarkers of cognitive decline in Parkinson's disease
Lin, C., & Wu, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.010 · Cited by 113
“In the recent decade, a genetic link between Gaucher disease (GD), a lysosomal disorder, and PD was proposed [149].”
BackgroundPrecision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Schneider, S. A., & Alcalay, R. N. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09705-7 · Cited by 108
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease
Avenali, M., Blandini, F., & Cerri, S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00097 · Cited by 104
“Moreover, the association between GBA1 mutation and PD development was confirmed by a large multicenter study demonstrating a significantly higher prevalence of GBA1 mutations among the PD population (Sidransky et al., 2009).”
BackgroundResultTherapy of Parkinson's Disease Subtypes
Marras, C., Chaudhuri, К. R., Titova, N., & Mestre, T. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00894-7 · Cited by 107
“GBA mutations are the most common genetic risk factor for PD, with 7 to 10% of PD patients carrying a GBAmutation [72, 73].”
BackgroundLysosomal integral membrane protein-2: A new player in lysosome-related pathology
Gonzalez, A., Valeiras, M., Sidransky, E., & Tayebi, N. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.12.005 · Cited by 98
Self-citationRon, I., Rapaport, D., & Horowitz, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq292 · Cited by 97
“The N370S mutation is a mild mutation, most prevalent among Ashkenazi Jews (49,50), which was found in association with PD (20,21,26,51).”
BackgroundResultModeling Parkinson’s Disease in Drosophila: What Have We Learned for Dominant Traits?
Xiong, Y., & Yu, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00228 · Cited by 93
Genes associated with Parkinson's disease: regulation of autophagy and beyond
Beilina, A., & Cookson, M. R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13266 · Cited by 93
Estes, R., Lin, B. C., Khera, A., & Davis, M. Y. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.788695 · Cited by 109
“Through further clinical and genome- wide association studies, GBA mutations are now recognized to increase the risk of developing PD by at least 5-fold compared to non-carriers making GBA mutations the strongest genetic risk factor for PD (Sidransky et al., 2009; Nalls et al., 2013).”
BackgroundSuzuki, M., Fujikake, N., Takeuchi, T., Kohyama‐Koganeya, A., Nakajima, K., Hirabayashi, Y., Wada, K., & Nagai, Y. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv372 · Cited by 106
Stuck in traffic: an emerging theme in diseases of the nervous system
Neefjes, J., & van der Kant, R. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.11.006 · Cited by 112
Matsui, H., Itô, J., Matsui, N., Uechi, T., Onodera, O., & Kakita, A. (2021) · Nature Communications · doi:10.1038/s41467-021-23452-x · Cited by 109
Mitochondrial dysfunction associated with glucocerebrosidase deficiency
Gegg, M. E., & Schapira, A. H. V. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.006 · Cited by 94
A “dose” effect of mutations in the GBA gene on Parkinson's disease phenotype
Thaler, A., Gurevich, T., Shira, A. B., Gana‐Weisz, M., Ash, E. L., Shiner, T., Orr‐Urtreger, A., Giladi, N., & Mirelman, A. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.12.014 · Cited by 102
Self-citationGBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis
Mallett, V. M., Ross, J. P., Alcalay, R. N., Ambalavanan, A., Sidransky, E., Dion, P. A., Rouleau, G. A., & Gan‐Or, Z. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000104 · Cited by 96
Self-citationThe Spectrum of Neurological Manifestations Associated with Gaucher Disease
Lal, T. R., & Sidransky, E. (2017) · Diseases · doi:10.3390/diseases5010010 · Cited by 102
“Studies in specific cohorts of patients with Parkinson’s disease and associated Lewy body disorders have indicated that these patients have an increased frequency of GBA1 mutations compared to control groups [27,28].”
Self-citationCurrent perspective of mitochondrial biology in Parkinson's disease
Kaidery, N. A., & Thomas, B. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.001 · Cited by 100
Sex Differences in Parkinson’s Disease: A Narrative Review
Cattaneo, C., & Pagonabarraga, J. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00687-6 · Cited by 106
Wang, C., Cai, Y., Gu, Z., Ma, J., Zheng, Z., Tang, B., Xu, Y., Zhou, Y., Feng, T., Wang, T., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.012 · Cited by 98
“…specific for Caucasians; GBA N370S mutations only for individuals of White and of Ashkenazi Jewish ethnicity) (Farrer et al., 2007; Lu et al., 2008; Sidransky et al., 2009), it is compelling to investigate whether the phenotypes of PD related to the 2 genes are also distinct in this population.”
Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons
Magalhaes, J., Gegg, M. E., Migdalska-Richards, A., & Schapira, A. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-19479-8 · Cited by 92
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Sjödin, S., Brinkmalm, G., Öhrfelt, A., Parnetti, L., Paciotti, S., Hansson, O., Hardy, J., Blennow, K., Zetterberg, H., & Brinkmalm, A. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0533-9 · Cited by 90
Drobny, A., Huarcaya, S. P., Dobert, J. P., Kluge, A., Bunk, J., Schlothauer, T., & Zunke, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119243 · Cited by 105
Homayoun, H. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201809040 · Cited by 113
Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions
Magdalinou, N., Lees, A. J., & Zetterberg, H. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307539 · Cited by 92
Schormair, B., Kemlink, D., Mollenhauer, B., Fiala, O., Machetanz, G., Roth, J., Berutti, R., Strom, T. M., Haslinger, B., Trenkwalder, C., et al. (2018) · Clinical Genetics · doi:10.1111/cge.13124 · Cited by 92
Stoker, T. B., Camacho, M., Winder‐Rhodes, S., Liu, G., Scherzer, C. R., Foltynie, T., Evans, J., Breen, D. P., Barker, R. A., & Williams‐Gray, C. H. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-322857 · Cited by 97
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models
Huarcaya, S. P., Drobny, A., Marques, A. R. A., Spiezio, A. D., Dobert, J. P., Balta, D., Werner, C. D., Rizo, T., Gallwitz, L., Bub, S., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2045534 · Cited by 105
Neurochemistry and the non-motor aspects of PD
Ferrer, I., López-Gonzalez, I., Carmona, M., Dalfó, E., Pujol, A., & Martínez, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.019 · Cited by 87
Neuroimaging in pre-motor Parkinson's disease
Barber, T. R., Klein, J. C., Mackay, C. E., & Hu, M. T. M. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.04.011 · Cited by 84
“Heterozygous GBA mutations occur in around 4–7% of sporadic cases and are 5 times more common in PD patients than in controls (Sidransky et al., 2009).”
Therapeutic potential of boosting NAD+ in aging and age-related diseases
Aman, Y., Qiu, Y., Tao, J., & Fang, E. F. (2018) · Translational Medicine of Aging · doi:10.1016/j.tma.2018.08.003 · Cited by 82
Giladi, N., Alcalay, R. N., Cutter, G., Gasser, T., Gurevich, T., Höglinger, G. U., MAREK, K. L., Pacchetti, C., Schapira, A. H. V., Scherzer, C. R., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00205-3 · Cited by 104
Self-citationDavies, S. E. W., Hallett, P. J., Moens, T. G., Smith, G. A., Mangano, E. N., Kim, H. T., Goldberg, A. L., Liu, J., Isacson, O., & Tofaris, G. K. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.12.011 · Cited by 98
“…are consistent with the notion that degradation of α-synuclein by lysosomes is an important pathway in PD pathogenesis: Mutations in glucocerebrosidase (GBA), a lysosomal enzyme linked to Gaucher's disease, are the most common genetic risk factor for sporadic PD (Sidransky et al., 2009).”
BackgroundLysosomal Ca2+Homeostasis and Signaling in Health and Disease
Lloyd-Evans, E., & Waller-Evans, H. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035311 · Cited by 88
Visual short-term memory deficits associated with GBA mutation and Parkinson’s disease
Zokaei, N., McNeill, A., Proukakis, C., Beavan, M. S., Jarman, P., Korlipara, P., Hughes, D. A., Mehta, A. B., Hu, M. T. M., Schapira, A. H. V., et al. (2014) · Brain · doi:10.1093/brain/awu143 · Cited by 94
Monaco, A., & Fraldi, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00037 · Cited by 95
“When GBA is mutated in homozygosis causes the Gaucher’s diseases, while when it is mutated in heterozygosis represents a major risk factor for PD (Sidransky et al., 2009).”
BackgroundUncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic
Lim, S., Tan, A. H., Ahmad‐Annuar, A., Okubadejo, N. U., Lohmann, K., Morris, H. R., Toh, T. S., Tay, Y. W., Lange, L. M., Bandrés‐Ciga, S., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00378-8 · Cited by 101
Self-citationLeija‐Salazar, M., Sedlazeck, F. J., Toffoli, M., Mullin, S., Mokretar, K., Athanasopoulou, M., Donald, A., Sharma, R., Hughes, D., Schapira, A. H. V., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.564 · Cited by 87
“Heterozygous GBA mutations are a significant risk factor for Parkinson's disease (PD; Mullin & Schapira, 2015; Sidransky et al., 2009), with evidence of longitudinal changes in many carriers suggestive of prodromal PD (Beavan et al., 2015).”
Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery
Arotçarena, M.-L., Teil, M., & Dehay, B. (2019) · Cells · doi:10.3390/cells8060565 · Cited by 97
“Similarly, patients with GD carrying heterozygous GBA mutations exhibited higher risks of developing PD [33].”
BackgroundSerum lipid alterations in GBA-associated Parkinson's disease
Guedes, L. C., Chan, R., Gomes, M. A., Conceição, V. A., Machado, R. B., Soares, T., Xu, Y., Gaspar, P., Carriço, J. A., Alcalay, R. N., et al. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.08.026 · Cited by 98
Baden, P., Maria Jose Perez, J., Raji, H., Bertoli, F., Kalb, S., Illescas, M., Spanos, F., Giuliano, C., Calogero, A. M., Oldrati, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37454-4 · Cited by 96
Self-citationAssociation Between Progranulin and Gaucher Disease
Jian, J., Zhao, S., Tian, Q.-Y., Liu, H., Zhao, Y., Chen, W.-C., Grunig, G., Torres, P. A., Wang, B. C., Zeng, B., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.004 · Cited by 93
Self-citationCognition in Parkinson's Disease
O’Callaghan, C., & Lewis, S. J. G. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.002 · Cited by 102
The endosomal pathway in Parkinson's disease
Perrett, R. M., Alexopoulou, Z., & Tofaris, G. K. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.009 · Cited by 104
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.